- Hydroxychloroquine, a 4-aminoquinoline DMARD, is used as a remission inducing agent in rheumatoid arthritis.
- Hydroxychloroquine is less toxic than chloroquine and produces a lower incidence of retinal damage than chloroquine.
- Sulfasalazine, a sulfa drug of DMARD class, is used in diseases like ulcerative colitis and rheumatoid arthritis.
- Disease modifying antirheumatic drugs are indicated in rheumatoid arthritis along with NSAIDs in patients with progressive disease.
- The beneficial effect of DMARDs is manifest only after 1-3 months of therapy.
- Prednisolone is an anti-rheumatic drug that affords symptomatic relief but does not bring about remission in rheumatoid arthritis.
- Leflunomide is a disease modifying anti-rheumatic drug whose active metabolite inhibits the enzyme dihydro-orotate dehydrogenase (DHODH).
- Sulfasalazine, a DMARD, is made up of two components, mesalazine (5-aminosalicyclic acid or 5-ASA) and a sulfa antibiotic, called sulfapyridine.
- Around 90% of the dose of sulfasalazine reaches the colon, where most of it is metabolized by bacteria into sulfapyridine and mesalazine (also known as 5-aminosalicylic acid). Both metabolites are active; most of the sulfapyridine is absorbed and then further metabolized, but most mesalazine is not, and remains in the colon.
- Sulfapyridine component of sulfasalazine is responsible for the therapeutic effect in rheumatoid arthritis while 5-ASA component of sulfasalazine is responsible for the therapeutic effect in ulcerative colitis.
- Home
- Pharm-D
- _Syllabus
- __Annual system
- __Semester system
- _Course materials
- __1st Prof.
- __2nd Prof.
- __3rd Prof.
- __4th Prof.
- __Final Prof.
- _Drugs Classifications
- _Past Papers
- Pharmacy Technicians books
- Solved Pharmacy MCQs
- Pharmacist Exams
- _KAPS Mock Exam
- _HAAD Mock Exam
- _MOH Mock Exam
- _DHA Mock Exam
- _NHRA Bahrain Exam
- _QCHP Qatar Exam
- _Gulf countries
- _GPAT
- Professional Books
- YouTube
0 Comments
If you have any suggestions or find some information inaccurate, plz let me know. Thanks.